In biotech, Boston reigns supreme, but its competitive edge is being challenged

For more than a decade, Boston has been the undisputed capital of the world’s life sciences industry. No other city really comes close.

There is more lab space in Boston and Cambridge than anywhere in the world. Billions of dollars in venture capital flow into the region fueling startups, while billions more come from the federal government to fund research. It’s an enviable economic engine that has nearly doubled biopharma employment over the past decade and powered our region’s prosperity.

But what about now?

To read the rest of this story subscribe to STAT+. Subscribe Log In